AZN’s Sexiest Early Stage Assets
AZN highlighted its sexiest early stage assets at #JPM2024
🚨 Upcoming noteworthy 2024 AZN early-stage readouts 📸
IO Bispecifics
$92B IO market by 2028 📸
Volrustomig (Ph2 solid tumors) - H1 2024
Rilvegostomig (Ph2 solid tumors) - H1 2024
Novel ADCs
$37B ADC market by 2028 📸
AZD8205 (Ph2 solid tumors) - H2 2024
AZD9592 (Ph1 solid tumors) - H2 2024
Metabolism portfolio
AZD5004 - H1 2024
AZD0780 (Ph1 dyslipidaemia) - H1 2024
AZD6234 (Ph1 obesity with related comorbidities) - H1 2024
Oligonucleotides
AZD2693 (Ph2 NASH) - H1 2024
AZD7503 (Ph1 NASH) - H2 2024
Click link to subscribe to get full access to our catalyst calendar...👇
🔗 https://www.bpiq.com/pricing
Article History:
1/31/24 AV
This article is not investment or legal advice.
#AZN
8 Views